Efficacy of Liraglutide in Patients with Glucocorticoid-induced Glucose Intolerance: A Case Study

Yamauchi Ichiro, Matsumoto Yoshihiro, Mitsuda Kanako, Yasuda Toshiko, Yoshida Yukiko, Nakano Atsuo, Tanaka Satsuki, Maeda Koji, Shintani Mitsuyo, Nishimura Haruo

doi:10.11213/tonyobyo.57.102

Bibliographic Information

Other Title

ステロイド投与中の血糖コントロールにおけるリラグルチドの有効性
症例報告ステロイド投与中の血糖コントロールにおけるリラグルチドの有効性
ショウレイホウコクステロイドトウヨチュウノケットウコントロールニオケルリラグルチドノユウコウセイ

Search this article

Abstract

Previous reports have suggested that glucagon-like-peptide 1 receptor agonists prevent glucocorticoid-induced glucose intolerance in healthy subjects. We investigated the clinical efficacy of liraglutide in patients with glucocorticoid-induced glucose intolerance based on the treatment course in five cases. In three cases, the patients presented with normal fasting blood glucose (105 mg/dl, 104 mg/dl, and 89 mg/dl), and liraglutide monotherapy successfully improved their glucose intolerance. In the other two cases, the patients both presented with mildly elevated fasting blood glucose (137 mg/dl, and 135 mg/dl), and combination therapy with liraglutide and insulin glargine was required. The present investigation suggests that liraglutide improves glucocorticoid-induced glucose intolerance, especially in patients with normal fasting blood glucose. Currently, glucocorticoid-induced glucose intolerance is frequently treated with multiple daily injections of insulin. We believe that liraglutide therapy is superior to multiple daily insulin injections for the following reasons: (1) a reduced number of injections, (2) a lower risk of hypoglycemia, (3) the lack of need for real-time dose adjustment.

Journal

Journal of the Japan Diabetes Society

Journal of the Japan Diabetes Society 57 (2), 102-107, 2014

THE JAPAN DIABETES SOCIETY

Keywords

Details 詳細情報について

Export